Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients.

Ten critically-ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii, S. maltophilia or NDM-producing K. pneumoniae received cefiderocol. All strains had MIC ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.